問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Tri-Service General Hospital (在職)

Division of Hematology & Oncology

Division of General Surgery

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of General Internal Medicine

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Hematology & Oncology

Taipei Medical University Hospital (在職)

Division of Hematology & Oncology

Linkou Chang Gung Medical Foundation (在職)

更新時間：2023-09-19

趙祖怡Chao, Tsu-Yi
  • Principal Investigator
  • Clinical Trial Experience (year) -23 years -4 個月

Recruiting Trial

29Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

趙祖怡

List

106Cases

2025-09-01 - 2028-09-01

Phase I/II

Completed
A Phase 1/2, First in Human Study of DCC 3116 as Monotherapy and in Combination with RAS/MAPK Pathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations

  • Condition/Disease

    Advanced or Metastatic Solid Tumors With RAS/MAPK Pathway Mutations

  • Test Drug

    DCC-3116

Participate Sites
4Sites

Recruiting4Sites

2020-07-01 - 2026-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2022-10-01 - 2026-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting3Sites

Recruiting4Sites

2023-05-01 - 2027-05-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
12Sites

Not yet recruiting9Sites

Recruiting1Sites

2023-06-30 - 2029-02-28

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Not yet recruiting9Sites

2010-08-01 - 2018-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2011-10-01 - 2025-06-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2007-11-14 - 2009-12-29

Phase II/III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2012-11-30 - 2017-06-30

Phase IV

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2021-04-01 - 2027-05-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Not yet recruiting17Sites

1 2 3 4 5 11
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB